[[ type === 'moc' ? 'MARKET ON CLOSE' : 'FREE WEBINAR' ]]
[[ timeLabel ]] WATCH LIVE:
Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Join Barchart Premier to attend LIVE "Market on Close" program each Friday with John Rowland. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or
Faster, Cleaner, Better.

Relmada Therapeutics Inc (RLMD)

Relmada Therapeutics Inc (RLMD)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Profile for [[ item.sessionDateDisplayLong ]]

Company Info

Relmada Therapeutics Inc 2222 PONCE DE LEON BLVD. 3RD FLOOR CORAL GABLES FL 33134 USA

www.relmada.com Employees: 17 P: 786-629-1376

Sector:

Medical

Description:

Relmada Therapeutics Inc. is a clinical stage, public specialty pharmaceutical company. The Company is developing LevoCap ER, an abuse resistant, once-a-day sustained release dosage form of the opioid analgesic levorphanol; d-methadone, the NDMA receptor antagonist for neurophatic pain; BuTab ER, an oral dosage form of the opioid analgesic buprenorphine and MepiGel, a FDA Orphan Drug designated topical formulation of the local anesthetic mepivacaine. Relmada Therapeutics Inc. is based in New York.

Key Statistics

Overview:

Market Capitalization, $K 781,416
Enterprise Value, $K 777,916
Shares Outstanding, K 104,888
Float, K 89,679
% Float 85.50%
Short Interest, K 6,193
Short Float 5.90%
Days to Cover 4.78
Short Volume Ratio 0.23
% of Insider Shareholders 14.50%
% of Institutional Shareholders 45.24%

Financials:

Annual Sales, $ 0 K
Annual Net Income, $ -57,390 K
Last Quarter Sales, $ 0 K
Last Quarter Net Income, $ -19,870 K
EBIT, $ -59,100 K
EBITDA, $ -59,100 K

Growth:

1-Year Return 1,812.82%
3-Year Return 134.65%
5-Year Return -80.35%
5-Year Revenue Growth 0.00%
5-Year Earnings Growth 61.94%
5-Year Dividend Growth 0.00%

Per-Share Information:

Most Recent Earnings -0.27 on 03/19/26
Next Earnings Date 05/12/26 [AMC]
Earnings Per Share ttm -1.45
EPS Growth vs. Prev Qtr 10.00%
EPS Growth vs. Prev Year 56.45%
Annual Dividend & Yield (Paid) 0.00 (0.00%)
Annual Dividend & Yield (Fwd) 0.00 (0.00%)
Dividend Payout Ratio 0.00%
Most Recent Split 1-4 on 09/30/19

RLMD Ratios

Ratio
Price/Earnings ttm 0.00
Price/Earnings forward N/A
Price/Earnings to Growth N/A
Return-on-Equity % -170.83%
Return-on-Assets % -145.58%
Profit Margin % 0.00%
Debt/Equity 0.00
Price/Sales N/A
Price/Cash Flow N/A
Price/Book 6.24
Book Value/Share 1.18
Interest Coverage -0.78
60-Month Beta 0.43
Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.